[{"id":"18969080-8eb0-4d96-a700-a81dd448f550","acronym":"SINTART2","url":"https://clinicaltrials.gov/study/NCT02099188","created_at":"2021-07-13T21:53:06.604Z","updated_at":"2024-07-02T16:35:53.438Z","phase":"Phase 2","brief_title":"Multidisciplinary Approach for Poor Prognosis Sinonasal Tumors in Inoperable Patients","source_id_and_acronym":"NCT02099188 - SINTART2","lead_sponsor":"Fondazione IRCCS Istituto Nazionale dei Tumori, Milano","biomarkers":" TP53","pipe":"","alterations":" ","tags":["TP53"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • docetaxel • 5-fluorouracil • doxorubicin hydrochloride • ifosfamide • etoposide IV • leucovorin calcium"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 27","initiation":"Initiation: 11/01/2013","start_date":" 11/01/2013","primary_txt":" Primary completion: 06/01/2020","primary_completion_date":" 06/01/2020","study_txt":" Completion: 01/01/2024","study_completion_date":" 01/01/2024","last_update_posted":"2023-03-13"},{"id":"c76b2924-526d-4c0c-91ca-abc674c755d0","acronym":"SINTART 1","url":"https://clinicaltrials.gov/study/NCT02099175","created_at":"2021-07-13T21:53:06.298Z","updated_at":"2024-07-02T16:35:53.426Z","phase":"Phase 2","brief_title":"Multidisciplinary Approach for Poor Prognosis Sinonasal Tumors in Operable Patients","source_id_and_acronym":"NCT02099175 - SINTART 1","lead_sponsor":"Fondazione IRCCS Istituto Nazionale dei Tumori, Milano","biomarkers":" TP53","pipe":"","alterations":" ","tags":["TP53"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • docetaxel • 5-fluorouracil • doxorubicin hydrochloride • ifosfamide • etoposide IV • leucovorin calcium"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 41","initiation":"Initiation: 11/01/2013","start_date":" 11/01/2013","primary_txt":" Primary completion: 01/01/2020","primary_completion_date":" 01/01/2020","study_txt":" Completion: 01/01/2024","study_completion_date":" 01/01/2024","last_update_posted":"2023-03-13"},{"id":"e33b78ef-4ce9-42bb-a172-8518d3e97f23","acronym":"","url":"https://clinicaltrials.gov/study/NCT00381940","created_at":"2021-01-28T18:52:11.240Z","updated_at":"2024-07-02T16:36:32.862Z","phase":"Phase 2","brief_title":"Bortezomib, Ifosfamide, and Vinorelbine Tartrate in Treating Young Patients With Hodgkin's Lymphoma That is Recurrent or Did Not Respond to Previous Therapy","source_id_and_acronym":"NCT00381940","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CD34 • NFKB1","pipe":"","alterations":" ","tags":["CD34 • NFKB1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e bortezomib • ifosfamide • vinorelbine tartrate • Neupogen (filgrastim)"],"overall_status":"Completed","enrollment":" Enrollment 26","initiation":"Initiation: 01/01/2007","start_date":" 01/01/2007","primary_txt":" Primary completion: 06/01/2008","primary_completion_date":" 06/01/2008","study_txt":" Completion: 12/31/2016","study_completion_date":" 12/31/2016","last_update_posted":"2021-03-24"},{"id":"36705e30-9803-4099-8555-99c1630f36b4","acronym":"","url":"https://clinicaltrials.gov/study/NCT00822848","created_at":"2021-01-18T03:07:40.456Z","updated_at":"2024-07-02T16:37:07.132Z","phase":"Phase 1","brief_title":"Sorafenib, Epirubicin, Ifosfamide, and Radiation Therapy Followed By Surgery in Treating Patients With High-Risk Stage II or Stage III Soft Tissue Sarcoma","source_id_and_acronym":"NCT00822848","lead_sponsor":"OHSU Knight Cancer Institute","biomarkers":" KDR","pipe":"","alterations":" ","tags":["KDR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e sorafenib • ifosfamide • epirubicin"],"overall_status":"Completed","enrollment":" Enrollment 18","initiation":"Initiation: 02/01/2009","start_date":" 02/01/2009","primary_txt":" Primary completion: 09/01/2012","primary_completion_date":" 09/01/2012","study_txt":" Completion: 04/30/2013","study_completion_date":" 04/30/2013","last_update_posted":"2018-09-07"}]